Nature Reviews Drug Discovery contents June 2013 Volume 12 Number 6 pp 405-483

Discovery Fast Track Competition If you have a novel drug discovery concept, and are affiliated with a U.S. or Canadian academic institution, you could win a chance to put your innovative research concept on an accelerated drug discovery path. GlaxoSmithKline (GSK) will provide state-of-the-art capabilities to scale biological reagents and develop assays to support high-throughput screening of millions of compounds against your target or pathway. Applications accepted until July 19. Register now.
TABLE OF CONTENTS
June 2013 Volume 12 Number 6
Impact Factor 29.008 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month  Featured article: Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases Lars Petter Jordheim, David Durantel, Fabien Zoulim & Charles Dumontet
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Outlook: Sleep Researchers are defining the various functions of sleep, from how we learn to the regulation of metabolism and immunity. New ways to treat troubled sleeping are being developed, and better sleep practice can help people with mood disorders. Access the Outlook free online for six months. Produced with support from: ResMed
In this issue p405 | doi:10.1038/nrd4039 Full Text
Comment: LifeTrain: towards a European framework for continuing professional development in biomedical sciences Mike Hardman, Cath Brooksbank, Claire Johnson, Christa Janko, Wolf See, Pierre Lafolie, Heinrich Klech, Patrice Verpillat & Hans Lindén p407 | doi:10.1038/nrd4026 Successful biomedical scientists learn throughout their careers. The LifeTrain project aims to optimize investments in learning to support the development of medicines in Europe and to encourage stronger interactions between industry and academia. Full Text | PDF
NEWS AND ANALYSIS		Top
All-oral HCV therapies near approval Man Tsuey Tse p409 | doi:10.1038/nrd4036 Gilead has filed the first interferon-free hepatitis C virus regimen for approval in the United States, but drug developers are making strides with better combinations. PDF
Integrin inhibitors go with the gut David Holmes p411 | doi:10.1038/nrd4037 Takeda has filed for European approval of vedolizumab in inflammatory bowel disease, potentially providing new hope for spurned integrin inhibitors. PDF
NEWS IN BRIEF Drug spending down p413 | doi:10.1038/nrd4046 PDF
Clinical trial transparency plans hit a snag p413 | doi:10.1038/nrd4047 PDF
Biotech "not completely out of the woods" p413 | doi:10.1038/nrd4048 PDF
BIOBUSINESS BRIEFS Regulatory watch: Enhanced chance of success for protein replacement therapies Sarah Crunkhorn p414 | doi:10.1038/nrd4027 PDF
BIOBUSINESS BRIEFS Trial watch: Opioid receptor blocker shows promise in Phase II depression trial Charlotte Harrison p415 | doi:10.1038/nrd4028 PDF
PATENT WATCH One valid claim is all that is needed Charlotte Harrison p416 | doi:10.1038/nrd4049 PDF
AN AUDIENCE WITH Menelas Pangalos Asher Mullard p418 | doi:10.1038/nrd4044 Menelas Pangalos, Executive Vice President of Innovative Medicines at AstraZeneca, discusses the company's R&D strategy. PDF
FROM THE ANALYST'S COUCH What matters most in commercial success: first-in-class or best-in-class? Ulrik Schulze & Michael Ringel p419 | doi:10.1038/nrd4035 It is common for several companies to be simultaneously pursuing promising new targets, and this analysis investigates the relative importance of market entry order and therapeutic impact on commercial success for drugs in the same class. PDF
RESEARCH HIGHLIGHTS Top Neurodegenerative diseases: Simple amyloids to provide protection in MS? p421 | doi:10.1038/nrd4032 PDF Analgesia: A new player in neuropathic pain pathogenesis p422 | doi:10.1038/nrd4031 PDF Anticancer drugs: Blocking RAS effects p422 | doi:10.1038/nrd4033 PDF Inflammatory disorders: Targeting TRAFs tames inflammation p423 | doi:10.1038/nrd4029 PDF G protein-coupled receptors: Pioneering Frizzled family receptor structure solved p424 | doi:10.1038/nrd4030 PDF IN BRIEF Anticancer drugs: A new target for melanoma | Animal models: Capturing AD features in a novel rat model | Malaria: In a class of their own | Nanotechnology: Going for gold alone PDF Drug Discovery JOBS of the week Associate Director - Small Molecule Oncology Drug Discovery Johnson & Johnson Cancer Research UK Career Development and Senior Cancer Research Fellowships The University of Sheffield A PhD student position available for Chemist at CNIC Spanish National Cardiovascular Research Center (CNIC) Process Chemist Merck Group Exciting Research Opportunities Available Queensland Institute of Medical Research More Science jobs from Drug Discovery EVENT Pediatric Drug Development 08.07.13 London, UK More science events from
Advertisement
The best in humanized mice. Study-ready cohorts of humanized NSG mice are readily available for shipment to your institution - or customized drug efficacy studies can be executed by JAX® In Vivo Pharmacology Services group. Learn more.
PERSPECTIVES		Top
OPINION The most transformative drugs of the past 25 years: a survey of physicians Aaron S. Kesselheim & Jerry Avorn p425 | doi:10.1038/nrd3977 There is substantial debate over the best approach for developing transformative drugs and how this might be supported. To help inform this debate by improving the understanding of the characteristics of transformative drug innovation, the authors surveyed a US-based group of ~180 expert physicians in 15 medical specialities, who identified the drugs that they considered to be the most transformative in their fields over the past 25 years, as well as key factors affecting their opinions. Abstract | Full Text | PDF | Supplementary information
REVIEWS		Top
Targeting long non-coding RNA to therapeutically upregulate gene expression Claes Wahlestedt p433 | doi:10.1038/nrd4018 Although originally believed to be non-functional, key roles for non-coding RNA (ncRNA) transcripts in the regulation of gene expression have now been revealed. Here, Wahlestedt provides an overview of the various subtypes of ncRNA, focusing on the emerging regulatory roles of long non-coding RNAs (lncRNAs) and their links to disease. The potential of targeting the natural antisense transcript subclass of lncRNAs using antisense oligonucleotides known as antagoNATs, to therapeutically upregulate gene expression, is assessed. Abstract | Full Text | PDF
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases Lars Petter Jordheim, David Durantel, Fabien Zoulim & Charles Dumontet p447 | doi:10.1038/nrd4010 Nucleoside analogues have been in clinical use for many years, but there are ongoing efforts to improve patient response rates and reduce side effects. Here, the authors highlight recent progress in the development of new nucleoside and nucleotide analogues for the treatment of cancer and viral diseases. Abstract | Full Text | PDF | Supplementary information
Pharmacological approaches to restore mitochondrial function Penelope A. Andreux, Riekelt H. Houtkooper & Johan Auwerx p465 | doi:10.1038/nrd4023 Dysfunctional mitochondria are implicated in rare, inherited mitochondrial diseases as well as a variety of common age-related disorders. Here, Auwerx and colleagues provide an overview of diseases that affect mitochondria, highlight strategies for therapeutically intervening in mitochondrial pathways and discuss screening strategies for drug identification. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Quantifying biased agonism: understanding the links between affinity and efficacy Sudarshan Rajagopal p483 | doi:10.1038/nrd3954-c1 Full Text | PDF
		Top
Reply: Measurements of ligand bias and functional affinity Terry Kenakin & Arthur Christopoulos p483 | doi:10.1038/nrd3954-c2 Full Text | PDF
Erratum: Maturing antibody-drug conjugate pipeline hits 30 Asher Mullard p483 | doi:10.1038/nrd4034 Full Text | PDF
Advertisement
SciBX Collections Macrocycles and constrained peptides This special collection explores the factors behind the growing interest in macrocycles and constrained peptides over the last five years and their effect on drug discovery. Click here to access the collection for free! Produced with support from: Aileron Therapeutics, Inc., Polypeptide Group, Polyphor LTD., Lanthiopharma B.V.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.